European regulators endorse Casgevy, paving way for approval of CRISPR-based therapy; FDA publishes new database of wayward clinical trial sponsors

Taking stock of the drug industry, from the lab to the medicine chest

December 15, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Paulo Amorim / VWPics via AP Images STAT+ | European regulators endorse Casgevy, paving way for approval of CRISPR-based therapy The world's first medicine based on CRISPR will almost certainly win approval in Europe, following an endorsement by a regulatory committee. By Andrew Joseph STAT+ | In response to criticism, FDA publishes new database of wayward clinical trial sponsors The agency has sent about 120 so-called pre-notices indicating a clinical trial sponsor or investigator failed to comply with a federal law. By Ed Silverman Listen: FTC v. biotech, Pfizer's kitchen sink, & Vertex's future We delve into the fallout over the FTC's move to block what looked like a humdrum biotech deal between Sanofi and Maze Therapeutics. By Damian Garde and Allison DeAngelis and Adam Feuerstein Alex Hogan/STAT STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser